Alpha Cognition Inc. Advances Alzheimer's Treatment with Strong Early Adoption of ZUNVEYL

Alpha Cognition Inc. (NASDAQ: ACOG) has made notable strides in the second quarter of 2025 with the commercialization of ZUNVEYL®, its treatment for Alzheimer's disease (AD), marking a significant step forward in addressing a critical healthcare challenge. The company reported early adoption in the U.S. long-term care (LTC) market and achieved a pivotal regulatory milestone in China, underscoring the global potential of its therapy.

ZUNVEYL, a benzgalantamine-based treatment, has been ordered in over 300 LTC facilities across priority regions by the end of the quarter, with 65% of these facilities placing repeat orders. This level of adoption signals strong clinical confidence and operational fit, as the sales team engaged more than 3,700 healthcare professionals, generating both new and repeat prescriptions. The treatment's cognitive and behavioral benefits, alongside a favorable tolerability profile, have been highlighted in clinician feedback.

A significant achievement for Alpha Cognition was securing its first national Medicare Part D contract, which requires no prior authorization, thereby enhancing patient access ahead of schedule. This development is particularly impactful given that Alzheimer's disease affects 7 million Americans, with over 11 million prescriptions written annually. However, more than half of patients discontinue treatment within a year due to side effects, highlighting the need for better-tolerated therapies like ZUNVEYL.

The LTC market, representing 36% of AD prescriptions and approximately $2 billion in value, is the initial focus for ZUNVEYL. The early success in this segment, coupled with Medicare coverage, addresses a critical barrier to access for a significant portion of the patient population. Additionally, Alpha Cognition anticipates generating revenues abroad in fiscal year 2026, opening a new market for its treatment.

Financially, Alpha Cognition reported $1.6 million in net product sales from ZUNVEYL in the second quarter of 2025, bringing year-to-date net product revenue to approximately $2.0 million. Licensing revenue from the CMS partnership totaled $0.08 million. The company's R&D expenses decreased to $0.32 million from $0.97 million a year ago, while SG&A expenses rose to $6.54 million from $1.43 million, reflecting investments in commercialization efforts. Despite a net operating loss of $5.74 million and a widened net loss to $10.49 million, Alpha Cognition ended the quarter with $39.4 million in cash and equivalents, providing an estimated two years of runway at current burn rates.

Looking ahead, Alpha Cognition is focused on supporting LTC homes and pharmacies in navigating the regulatory landscape and aims to secure another national contract before the end of the year. The company's progress in the Alzheimer's treatment market, both in the U.S. and internationally, represents a beacon of hope for millions of patients and their families, offering a potential improvement in quality of life and disease management.